RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients

Figure 2

Kaplan-Meier plots of patients for disease-free survival (DFS) grouped by vascular tumor thrombus, KRAS mutation status, and RAS/BRAF mutation status. The DFS was significantly worse in patients with vascular tumor thrombus, with a median DFS of 259 days versus 578 days for nonvascular tumor thrombus patients () (a). There was no significant difference in DFS between KRAS mutant (MT) and wild type (WT) patients (median DFS 313 days versus 590 days, ) (b) or between RAS/BRAF mutant patients and wild type patients (median DFS 339 days versus 519 days, ) (c).

(a)

(b)

(c)